Neurorehabilitation News

The FDA has granted 510(k) clearance to a Canadian neuroimaging company for its quantitative imaging software, which assists neurologists and radiologists dealing with brain white matter issues for adjunctive care.

A Virginia-based biotech company has announced dosing of the first patient in a phase 2 clinical trial examining safety and efficacy of its investigational anti-inflammatory peptide, RLS-0071, to treat hypoxic ischemic encephalopathy in newborns.

Utilization of a teleneurology program by U.S. military veterans resulted in more efficient care compared with the community standard, and resulted in a high level of satisfaction, per research from the Journal of General Internal Medicine.

Rates of new-onset mental health conditions were higher in U.S. soldiers with a history of military-related traumatic brain injury, while increased risk for suicide was both directly and indirectly associated with TBI history.

The U.S. Department of Defense has awarded $11.4 million to a Boston-based biotherapeutics firm to advance its novel oral prodrug of endogenous allopregananolone, LYT-300, to treat Fragile X-associated Tremor Ataxia syndrome.

NYU Langone Hospitals was named the top hospital in the United States for neurology and neurosurgery by the U.S. News & World Report’s annual Best Hospitals survey.

A clinical-stage biopharmaceutical company and a global contract research organization have partnered to support the ongoing development of investigational, psychedelic therapeutics to treat a range of psychiatric disorders.

The FDA has granted breakthrough therapy designation to an investigational antisense nucleotide therapeutic to treat individuals with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.

A Southern California-based neuroscience company has announced initiation of a phase 2 clinical trial to evaluate the safety and efficacy of investigational therapeutic ENX-102 in those with generalized anxiety disorder.